GNA & Boehringer collaborate on ASF diagnostic test development
Category: #health  By Pankaj Singh  Date: 2019-02-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

GNA & Boehringer collaborate on ASF diagnostic test development
  • Both the companies will come up with holistic solutions for farmers, veterinarians, and the food producing industry.
  • The partnership aims to develop a diagnostic test for ASF.

Research-driven pharma conglomerate Boehringer Ingelheim has joined forces with GNA Biosolutions, in a bid to accelerate the development of a rapid ASF (African swine fever) diagnostic test. If reports are to be believed, the test that would be developed via the research partnership between Boehringer and the German molecular technology company will be used in consort with the latters portable molecular diagnostic platform and will aim to support the fight against the spread of this disease worldwide.

Speaking on the partnership, Rolf-Dieter Günther, Global Head, Diagnostics & Monitoring Animal Health, Boehringer Ingelheim, stated that in partnership with GNA, the company aims to come up with holistic solutions for farmers, veterinarians, and the food producing industry as a whole. The targeted platform will be designed to enable quicker decision-making based on the availability of highly comprehensive diagnostic data, Rolf-Dieter Günther further asserted.

For the uninitiated, ASF is a highly fatal swine infection that leads to severe clinical diseases. There is no current treatment for ASF, and no effective vaccines are available either. It has been reported that the massive outbreaks of ASF across Vietnam and China have been negatively impacting pork prices and demand since quite a while. As per a press release by Boehringer Ingelheim, ASF outbreaks led to more than 600,000 pigs culled in China alone, since the last few months.

Lars Ullerich, Managing Director & Co-founder, GNA Biosolutions, stated that this partnership stresses on the role that the company plays in the robustly expanding extra-laboratory diagnostics industry and also extends the application scope of GNA’s Pulse Controlled Amplification technology into animal protection.

As per reliable sources, neither GNA Biosolutions nor Boehringer Ingelheim have revealed any financial information pertaining to the said agreement so far.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
By Pankaj Singh

The manuscript includes data of the first four trial participants that were treated with RP-L102 under the Phase 1/2 FANCOLEN-I study.   First RP-L102 trail data demonstrates increase in bone marrow engraftment levels, which further leads to...

Shopify buys 6 River Systems for $450M to grow its fulfillment network
Shopify buys 6 River Systems for $450M to grow its fulfillment network
By Pankaj Singh

Acquisition of 6 River Systems seems to be an attempt to accelerate the growth in delivery of daily packages. The deal would further expand the reach of the Shopify Fulfillment Network, which utilizes machine learning to ensure lower shipping cost...

Genentech to present new data from neuroscience portfolio at ECTRIMS
Genentech to present new data from neuroscience portfolio at ECTRIMS
By Pankaj Singh

The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.   The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neur...